335 related articles for article (PubMed ID: 24391143)
1. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.
Zou JX; Duan Z; Wang J; Sokolov A; Xu J; Chen CZ; Li JJ; Chen HW
Mol Cancer Res; 2014 Apr; 12(4):539-49. PubMed ID: 24391143
[TBL] [Abstract][Full Text] [Related]
2. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark.
Revenko AS; Kalashnikova EV; Gemo AT; Zou JX; Chen HW
Mol Cell Biol; 2010 Nov; 30(22):5260-72. PubMed ID: 20855524
[TBL] [Abstract][Full Text] [Related]
3. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
[TBL] [Abstract][Full Text] [Related]
4. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.
Kalashnikova EV; Revenko AS; Gemo AT; Andrews NP; Tepper CG; Zou JX; Cardiff RD; Borowsky AD; Chen HW
Cancer Res; 2010 Nov; 70(22):9402-12. PubMed ID: 20864510
[TBL] [Abstract][Full Text] [Related]
5. Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNA‑damaging chemotherapy agents and radiation.
Duan Z; Andrews NP; Chen CZ; Fan M; Wang J; Shen J; Li JJ; Chen HW
Oncol Rep; 2020 Jan; 43(1):318-327. PubMed ID: 31789405
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer.
Li TF; Zeng HJ; Shan Z; Ye RY; Cheang TY; Zhang YJ; Lu SH; Zhang Q; Shao N; Lin Y
Cancer Cell Int; 2020; 20():123. PubMed ID: 32322170
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells.
Jin ML; Kim YW; Jin HL; Kang H; Lee EK; Stallcup MR; Jeong KW
Int J Cancer; 2018 Dec; 143(11):2871-2883. PubMed ID: 30191958
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
10. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
Vesuna F; Lisok A; Kimble B; Domek J; Kato Y; van der Groep P; Artemov D; Kowalski J; Carraway H; van Diest P; Raman V
Oncogene; 2012 Jul; 31(27):3223-34. PubMed ID: 22056872
[TBL] [Abstract][Full Text] [Related]
11. ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification.
Zou JX; Revenko AS; Li LB; Gemo AT; Chen HW
Proc Natl Acad Sci U S A; 2007 Nov; 104(46):18067-72. PubMed ID: 17998543
[TBL] [Abstract][Full Text] [Related]
12. Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma.
Li Q; Qiu J; Yang H; Sun G; Hu Y; Zhu D; Deng Z; Wang X; Tang J; Jiang R
Cancer Lett; 2020 Jul; 482():112-125. PubMed ID: 31733289
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.
De S; Cipriano R; Jackson MW; Stark GR
Cancer Res; 2009 Oct; 69(20):8035-42. PubMed ID: 19789344
[TBL] [Abstract][Full Text] [Related]
14. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer.
Zou JX; Guo L; Revenko AS; Tepper CG; Gemo AT; Kung HJ; Chen HW
Cancer Res; 2009 Apr; 69(8):3339-46. PubMed ID: 19318566
[TBL] [Abstract][Full Text] [Related]
15. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
[TBL] [Abstract][Full Text] [Related]
16. Deregulated E2F and the AAA+ coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer.
Hsia EY; Kalashnikova EV; Revenko AS; Zou JX; Borowsky AD; Chen HW
Mol Cancer Res; 2010 Feb; 8(2):183-93. PubMed ID: 20124470
[TBL] [Abstract][Full Text] [Related]
17. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
19. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
[TBL] [Abstract][Full Text] [Related]
20. SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor α-positive breast cancer cells.
Jin ML; Yang L; Jeong KW
Theranostics; 2022; 12(13):5761-5775. PubMed ID: 35966598
[No Abstract] [Full Text] [Related]
[Next] [New Search]
